Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Company Overview - Verve Therapeutics is a clinical-stage company focused on developing a new class of genetic medicines aimed at treating cardiovascular disease, transitioning from chronic therapies to single-course gene editing medicines [3] - The company is publicly traded on Nasdaq under the ticker symbol VERV [3] Lead Programs - The lead programs include VERVE-102, VERVE-201, and VERVE-301, which target key cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a) [3] - VERVE-102 aims to permanently turn off the PCSK9 gene in the liver, initially targeting heterozygous familial hypercholesterolemia (HeFH) and eventually patients with established atherosclerotic cardiovascular disease (ASCVD) [3] - VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, focusing on refractory hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [3] - VERVE-301 targets the LPA gene to reduce Lp(a) levels, which is an independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis [3] Upcoming Events - Sekar Kathiresan, M.D., co-founder and CEO of Verve Therapeutics, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 9 a.m. ET in New York [1] - A live webcast of the event will be available on the company's investor section of the website and will be archived for 90 days [2]